Published in Sports Health on September 01, 2012
Letter to the editor. Sports Health (2013) 0.75
Letter to the editor response. Sports Health (2013) 0.75
Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med (1998) 2.32
Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs (1990) 2.29
Effect of ketorolac tromethamine on bleeding and on requirements for analgesia after total knee arthroplasty. J Bone Joint Surg Am (1995) 2.10
Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA (1996) 1.90
Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum (2008) 1.58
Parenteral ketorolac: the risk for acute renal failure. Ann Intern Med (1997) 1.53
Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs (1997) 1.52
Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. Eur J Clin Pharmacol (1988) 1.40
Use of prescription drugs in athletes. Sports Med (2008) 1.29
The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine (Phila Pa 1976) (1998) 1.19
Non-steroidal anti-inflammatory drugs for athletes: an update. Ann Phys Rehabil Med (2010) 1.04
Prevalence, attitudes, and behaviors related to the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in student athletes. J Adolesc Health (2002) 1.02
Practical management: nonsteroidal antiinflammatory drug (NSAID) use in athletic injuries. Clin J Sport Med (2006) 1.01
Benefits and risks of using local anaesthetic for pain relief to allow early return to play in professional football. Br J Sports Med (2002) 0.99
Anti-inflammatory agents and renal function. Semin Arthritis Rheum (2002) 0.94
Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular administration in healthy volunteers. J Clin Pharmacol (2007) 0.91
Comparison of the effect of intravenous ketoprofen, ketorolac and diclofenac on platelet function in volunteers. Acta Anaesthesiol Scand (1997) 0.90
Analgesics and anti-inflammatory medications in sports: use and abuse. Pediatr Clin North Am (2010) 0.88
High dose nonsteroidal anti-inflammatory drugs compromise spinal fusion. Can J Anaesth (2005) 0.88
Painkilling drugs in collegiate athletics: knowledge, attitudes, and use of student athletes. J Drug Educ (2000) 0.86
Clinical pharmacokinetics of ketorolac tromethamine. Clin Pharmacokinet (1992) 0.84
Inhibition of perioperative platelet aggregation using toradol (ketorolac). Ann Plast Surg (1993) 0.81
Injections and return to play. Curr Sports Med Rep (2004) 0.81
Non-steroidal anti-inflammatory drugs in athletes. Br J Sports Med (2006) 0.80
Comparison of oral ketorolac and hydrocodone for pain relief after anterior cruciate ligament reconstruction. Arthroscopy (1998) 0.79
Ketorolac use in the national football league: prevalence, efficacy, and adverse events. Phys Sportsmed (2002) 0.79
Intramuscular ketorolac injections in the athlete. Sports Health (2012) 0.78
Effect of ketorolac tromethamine (Toradol) on ecchymosis following anterior cruciate ligament reconstruction. Am J Knee Surg (1995) 0.78
Pain medications in the locker room: to dispense or not. Curr Sports Med Rep (2007) 0.78
Comparison of ketorolac and opioid analgesics in postoperative ACL reconstruction outpatient pain control. Arthroscopy (1993) 0.78
Athletes, nonsteroidal anti-inflammatory drugs, coxibs, and the gastrointestinal tract. Curr Sports Med Rep (2002) 0.77
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med (2002) 10.52
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med (2003) 5.47
Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med (2007) 3.11
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis (2003) 2.68
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int (2003) 2.43
Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int (2004) 2.38
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension (2008) 2.24
Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. Kidney Int (2004) 2.16
Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol (2004) 2.08
Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis (2011) 2.05
Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS). Clin Transl Sci (2012) 1.76
Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial. Hypertension (2011) 1.65
A conceptual framework to study medication adherence in older adults. Am J Geriatr Pharmacother (2004) 1.54
Sustaining the Clinical and Translational Research Workforce: Training and Empowering the Next Generation of Investigators. Acad Med (2015) 1.52
Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study. Am J Kidney Dis (2007) 1.50
Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis (2007) 1.46
BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation (2002) 1.42
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis (2012) 1.38
Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease. J Am Soc Nephrol (2006) 1.38
A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension. J Am Soc Nephrol (2004) 1.37
Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients. Am J Kidney Dis (2007) 1.32
The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant (2003) 1.30
Urea space and total body water measurements by stable isotopes in patients with acute renal failure. Kidney Int (2004) 1.22
Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol (2003) 1.20
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis (2011) 1.18
Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. Clin Pharmacol Ther (2005) 1.16
Association of achieved dialysis dose with mortality in the hemodialysis study: an example of "dose-targeting bias". J Am Soc Nephrol (2005) 1.16
Intradialytic hypertension and the association with interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol (2011) 1.10
Health care and medication costs and use among older adults with heart failure. Am J Med (2004) 1.06
Association between adherence to diuretic therapy and health care utilization in patients with heart failure. Pharmacotherapy (2003) 1.03
Methodology of an ongoing, randomized, controlled trial to improve drug use for elderly patients with chronic heart failure. Am J Geriatr Pharmacother (2004) 1.01
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. Eur J Heart Fail (2009) 1.00
Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction. Clin J Am Soc Nephrol (2012) 1.00
Current update in the management of diabetic nephropathy. Curr Diabetes Rev (2013) 0.98
Metagenome and metaproteome analyses of microbial communities in mesophilic biogas-producing anaerobic batch fermentations indicate concerted plant carbohydrate degradation. Syst Appl Microbiol (2013) 0.95
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis (2009) 0.95
Inflammation and inverse associations of body mass index and serum creatinine with mortality in hemodialysis patients. J Ren Nutr (2007) 0.93
The cost-effectiveness of single-row compared with double-row arthroscopic rotator cuff repair. J Bone Joint Surg Am (2012) 0.91
Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol (2011) 0.90
Patellar tendon ruptures in National Football League players. Am J Sports Med (2011) 0.89
The MetaProteomeAnalyzer: a powerful open-source software suite for metaproteomics data analysis and interpretation. J Proteome Res (2015) 0.89
Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC Cardiovasc Disord (2012) 0.88
Controversies in COX-2 selective inhibition. J Rheumatol (2002) 0.86
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension (2012) 0.86
Metaproteome analysis to determine the metabolically active part of a thermophilic microbial community producing biogas from agricultural biomass. Can J Microbiol (2012) 0.85
Direct toxic effects of aqueous extract of cigarette smoke on cardiac myocytes at clinically relevant concentrations. Toxicol Appl Pharmacol (2009) 0.84
A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200 mg weekly versus placebo for 6 months in healthy volunteers. Am J Trop Med Hyg (2009) 0.84
Systemic amyloidosis presenting as chronic diarrhea in a patient with ankylosing spondylitis. J Clin Rheumatol (2010) 0.84
A model for engaging public-private partnerships. Clin Transl Sci (2011) 0.84
Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. Clin Pharmacol Ther (2005) 0.82
Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination. Am J Hypertens (2009) 0.81
Indicators of cocaine exposure and preterm birth. Obstet Gynecol (2002) 0.81
Hypertension and the kidney. Semin Nephrol (2005) 0.81
Medication and dietary compliance beliefs in heart failure. West J Nurs Res (2005) 0.80
Identification and management of albuminuria in the primary care setting. J Clin Hypertens (Greenwich) (2011) 0.79
Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: report of the national analgesic nephropathy study. J Am Soc Nephrol (2006) 0.79
Living kidney donation and hypertension risk. Lancet (2007) 0.79
Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy. Vasc Med (2004) 0.78
Risk of hyperkalemia associated with selective COX-2 inhibitors. Pharmacoepidemiol Drug Saf (2010) 0.78
Comparison of Ambulatory Blood Pressure Patterns in Patients With Intradialytic Hypertension and Hemodialysis Controls. Kidney Blood Press Res (2016) 0.77
Pharmacogenetics and healthcare outcomes in patients with chronic heart failure. Eur J Clin Pharmacol (2012) 0.77
Statements of Agreement From the Targeted Evaluation and Active Management (TEAM) Approaches to Treating Concussion Meeting Held in Pittsburgh, October 15-16, 2015. Neurosurgery (2016) 0.76
Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens (2009) 0.76
Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. Br J Clin Pharmacol (2004) 0.76
Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther (2011) 0.75
Letter to the editor response. Sports Health (2013) 0.75
Interdialytic ambulatory blood pressure in patients with intradialytic hypertension. Curr Opin Nephrol Hypertens (2012) 0.75
Extracellular Volume Overload and Increased Vasoconstriction in Patients With Recurrent Intradialytic Hypertension. Kidney Blood Press Res (2016) 0.75
Transition to Independence: Characteristics and Outcomes of Mentored Career Development (KL2) Scholars at Clinical and Translational Science Award Institutions. Acad Med (2017) 0.75
Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients. NDT Plus (2009) 0.75
MPA Portable: a Stand-alone Software Package for Analyzing Metaproteome Samples on the Go. Anal Chem (2017) 0.75
Application of an interferometric phase contrast method to fabricate arbitrary diffractive optical elements. Appl Opt (2008) 0.75